Ankit Mahadevia, Director at Spero Therapeutics, Inc. (SPRO), sold 6,572 shares at $1.97 ($13K) on 2025-08-28, disclosed to the SEC on 2025-09-03.
Open-market sale of $13k SPRO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |
| SPRO | SELL | 2023-02-06 | $22K | — | Filing → |